Mostrar el registro sencillo del ítem

dc.contributor.author
Miksztowicz, Veronica Julieta  
dc.contributor.author
Lucero, Diego Martín  
dc.contributor.author
Zago, Valeria  
dc.contributor.author
Cacciagiú, Leonardo Damian  
dc.contributor.author
Lopez, Graciela Ines  
dc.contributor.author
Gonzalez Ballerga, E.  
dc.contributor.author
Sordá, J.  
dc.contributor.author
Fassio, E.  
dc.contributor.author
Schreier, Laura Ester  
dc.contributor.author
Berg, Gabriela Alicia  
dc.date.available
2025-09-29T15:57:31Z  
dc.date.issued
2012-09  
dc.identifier.citation
Miksztowicz, Veronica Julieta; Lucero, Diego Martín; Zago, Valeria; Cacciagiú, Leonardo Damian; Lopez, Graciela Ines; et al.; Hepatic lipase activity is increased in non‐alcoholic fatty liver disease beyond insulin resistance; John Wiley & Sons Ltd; Diabetes/metabolism Research and Reviews; 28; 6; 9-2012; 535-541  
dc.identifier.issn
1520-7552  
dc.identifier.uri
http://hdl.handle.net/11336/272221  
dc.description.abstract
Background and objective Hepatic lipase is a lipolytic enzyme mostly synthesized and localized at the surface of liver sinusoidal capillaries, which hydrolyses triglycerides and phospholipids of intermediate density, large low density (LDL) and high density lipoproteins. Hepatic lipase activity is increased in insulin resistant states. Non-alcoholic fatty liver disease (NAFLD) is characterized by insulin resistance. However, at present, no data are available regarding the behaviour of hepatic lipase with regard to the degree of hepatic steatosis. Our aim was to evaluate hepatic lipase activity in NAFLD patients and its relationship to the severity of hepatic steatosis. Design and patients We studied 48 patients with NAFLD (diagnosed by ultrasonography and confirmed by liver biopsy) and 30 controls. Steatosis was semi-quantitatively assessed and considered as mild or grade 1, moderate or grade 2 and severe or grade 3. Measurements: hepatic lipase activity, lipid and lipoprotein profile (including intermediate density lipoproteins and dense LDL), adiponectin, insulin, glucose and high sensitivity C-reactive protein were measured. Homeostasis model assessment for insulin resistance (HOMA) index was calculated. Results Patients with hepatic steatosis presented with higher hepatic lipase activity, HOMA and dense LDL and lower levels of adiponectin, high density lipoproteins, cholesterol and apoA-I. Hepatic lipase activity positively correlated significantly with the severity of hepatic steatosis. Hepatic lipase correlated with a more atherogenic profile and persisted higher in patients even after corrected for age, gender, body mass index, HOMA and adiponectin. Conclusion The higher hepatic lipase activity in NAFLD patients contributes to a more atherogenic profile linked to increased cardiovascular risk, beyond the insulin resistance and the reduction in adiponectin.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
John Wiley & Sons Ltd  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
HEPATIC LIPASE  
dc.subject
INSULIN RESISTANCE  
dc.subject
ADIPONECTIN  
dc.subject
CARDIOVASCULAR RISK  
dc.subject.classification
Otras Ciencias de la Salud  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Hepatic lipase activity is increased in non‐alcoholic fatty liver disease beyond insulin resistance  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2025-09-01T12:30:47Z  
dc.journal.volume
28  
dc.journal.number
6  
dc.journal.pagination
535-541  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Miksztowicz, Veronica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Lucero, Diego Martín. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Zago, Valeria. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Cacciagiú, Leonardo Damian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina  
dc.description.fil
Fil: Lopez, Graciela Ines. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina  
dc.description.fil
Fil: Gonzalez Ballerga, E.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina  
dc.description.fil
Fil: Sordá, J.. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina  
dc.description.fil
Fil: Fassio, E.. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina  
dc.description.fil
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina  
dc.description.fil
Fil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.journal.title
Diabetes/metabolism Research and Reviews  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/dmrr.2312  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/dmrr.2312